The investigators hypothesize that JAK 1/2 inhibition with ruxolitinib, an FDA approved
treatment for intermediate or high-risk myelofibrosis, could have a similar effect in
patients with severe COVID-19, quelling the immune-hyperactivation, allowing for clearance of
the virus and reversal of the disease manifestations.